CADDEO, ANDREA MARCO
 Distribuzione geografica
Continente #
EU - Europa 3.511
NA - Nord America 188
AS - Asia 85
SA - Sud America 8
Totale 3.792
Nazione #
IT - Italia 3.427
US - Stati Uniti d'America 185
CN - Cina 43
SE - Svezia 43
SG - Singapore 33
FI - Finlandia 9
DE - Germania 8
BR - Brasile 7
GB - Regno Unito 7
AT - Austria 6
NL - Olanda 5
CA - Canada 2
ES - Italia 2
KR - Corea 2
TR - Turchia 2
AZ - Azerbaigian 1
BY - Bielorussia 1
CO - Colombia 1
FR - Francia 1
IN - India 1
KG - Kirghizistan 1
KZ - Kazakistan 1
MX - Messico 1
MY - Malesia 1
PT - Portogallo 1
RU - Federazione Russa 1
Totale 3.792
Città #
Cagliari 3.163
Uta 211
Boardman 53
Nyköping 42
Shanghai 21
Santa Clara 20
Singapore 16
Helsinki 8
Los Angeles 8
Pisa 7
Bologna 5
Cerreto Guidi 5
Fairfield 5
Nuremberg 5
Rome 5
Chandler 4
Amsterdam 3
Boston 3
Florence 3
Livorno 3
San Diego 3
Vienna 3
Woodbridge 3
Wuxi 3
Ann Arbor 2
Bari 2
Houston 2
Istanbul 2
Jinan 2
Quarrata 2
Seongnam-si 2
Wuhan 2
Xi'an 2
Almaty 1
Ashburn 1
Asolo 1
Baku 1
Barcelona 1
Bishkek 1
Cambridge 1
Campi Bisenzio 1
Enschede 1
Guangzhou 1
Hamburg 1
Islington 1
Itaipava 1
Kilburn 1
Lappeenranta 1
Longyan 1
Manchester 1
Medellín 1
Mexico City 1
Milan 1
Mossoró 1
Mountain View 1
New Bedfont 1
New York 1
Novara 1
Oliena 1
Pune 1
Raul Soares 1
Rio Claro 1
Rolim de Moura do Guaporé 1
San Giuliano Milanese 1
Siena 1
Sioux Falls 1
São Bernardo do Campo 1
São Vicente 1
Toronto 1
Turin 1
Xiamen 1
Totale 3.658
Nome #
Tg68, a novel thyroid hormone receptor‐β agonist for the treatment of NAFLD 856
Novel thyroid hormone receptor-beta agonist TG68 safely induces hepatic fat reduction in a non-alcoholic steatohepatitis rat model 669
Novel thyroid hormone receptor-beta agonist TG68 safely induces hepatic fat reduction in a non-alcoholic steatohepatitis rat model 528
Novel thyroid hormone receptor beta agonist TG68 safely induces hepatic fat loss reduction in a NASH mouse model 344
Novel thyroid hormone receptor-beta agonist TG68 safely induces hepatic fat reduction in a non-alcoholic steatohepatitis rat model 334
Potential use of TG68 - A novel thyromimetic - for the treatment of non-alcoholic fatty liver (NAFLD)-associated hepatocarcinogenesis 260
Metabolic reprogramming in Nrf2-driven proliferation of normal rat hepatocytes 213
Identification of novel loss of function variants in MBOAT7 resulting in intellectual disability 79
LPIAT1/MBOAT7 depletion increases triglyceride synthesis fueled by high phosphatidylinositol turnover 73
MBOAT7 is anchored to endomembranes by six transmembrane domains 65
The TM6SF2 E167K genetic variant induces lipid biosynthesis and reduces apolipoprotein B secretion in human hepatic 3D spheroids 59
IL32 downregulation lowers triglycerides and type I collagen in di-lineage human primary liver organoids 58
Molecular analysis of three known and one novel LPL variants in patients with type I hyperlipoproteinemia 57
The role of MBOAT7 on fatty liver disease 55
LPIAT1/MBOAT7 contains a catalytic dyad transferring polyunsaturated fatty acids to lysophosphatidylinositol 42
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 41
PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis 39
MBOAT7 in liver and extrahepatic diseases 28
Increased secretion of adipocyte-derived extracellular vesicles is associated with adipose tissue inflammation and the mobilization of excess lipid in human obesity 18
3D culture models to study pathophysiology of steatotic liver disease 18
Totale 3.836
Categoria #
all - tutte 8.249
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.249


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202289 0 0 0 0 0 0 0 5 30 15 23 16
2022/2023538 24 22 35 22 60 44 64 42 53 64 79 29
2023/20241.083 47 43 64 66 97 125 169 115 57 56 88 156
2024/20252.126 619 640 228 215 120 104 175 25 0 0 0 0
Totale 3.836